Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- RTO +7.4%, QS +6.8%, IIIN +6.2%, ALLE +5.9%, SEIC +5.3%, KNX +4.4%, LBRT +4.2%, POOL +4.1%, SPOT +4.0%, LMT +3.8%, DOW +3.0%, PG +2.8%, R +2.8%, CURB +2.5%, KMI +2.3%, CSX +2.1%, SLG +2.1%, FCFS +2.0%, RS +1.7%, NTST +1.5%, VLY +1.5%
Other news:
- BHVN +34.0% (FDA accepted Biohaven's Vyglxia NDA resubmission for review and set a first-quarter 2027 decision goal.)
- RAPP +3.8% (CFO purchased 5,500 shares at $26.10, totaling approximately $143,550.)
- ATOM +3.3% (Signed a joint development agreement with IQE to develop MST-enabled RF GaN-on-silicon wafers.)
- KRRO +2.3% (Reported KRRO-111 achieved over 95% mRNA editing and reduced pathogenic hepatic Z-AAT by up to 95% preclinically.)
- USO +1.6% (U.S. and Israel are reportedly preparing post-election strikes on Iran, potentially targeting its energy infrastructure.)
- MTDR +1.0% (Raised its quarterly dividend 17% to $0.4375 per share, beginning in the fourth quarter.)
- QGEN +1.0% (Agreed to EQT Private Equity's €46.50-per-share all-cash takeover offer, valuing the company at approximately €10.8 billion.)
Analyst comments:
- WHF +3.4% (Upgraded to Outperform from Market Perform at Raymond James with a $9 price target.)
- PBLS +2.2% (Initiated with a Buy rating and $40 price target at H.C. Wainwright.)
- IONS +1.9% (Upgraded to Outperform from Market Perform at BMO Capital with a $66 target.)
- RNA +1.0% (Initiated with a Buy rating and $15 price target at Roth Capital.)